Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 508.64M | 500.89M | 503.88M | 488.40M | 488.10M | 434.39M |
Gross Profit | 224.66M | 223.20M | 221.99M | 215.47M | 222.69M | 217.83M |
EBITDA | 58.83M | 61.30M | 66.58M | 66.37M | 80.83M | 92.43M |
Net Income | 14.81M | 16.59M | 17.22M | -103.46M | 33.37M | 50.87M |
Balance Sheet | ||||||
Total Assets | 743.25M | 743.51M | 772.35M | 802.17M | 928.58M | 744.20M |
Cash, Cash Equivalents and Short-Term Investments | 103.19M | 103.09M | 102.80M | 80.13M | 77.51M | 161.69M |
Total Debt | 2.83M | 3.52M | 5.48M | 21.35M | 7.44M | 13.33M |
Total Liabilities | 78.55M | 73.36M | 77.06M | 104.52M | 100.09M | 99.85M |
Stockholders Equity | 743.25M | 670.15M | 695.29M | 697.65M | 828.49M | 644.36M |
Cash Flow | ||||||
Free Cash Flow | 76.97M | 68.66M | 45.16M | 40.39M | 21.03M | 59.96M |
Operating Cash Flow | 71.01M | 77.83M | 73.27M | 62.08M | 55.24M | 106.97M |
Investing Cash Flow | -20.80M | -13.58M | -4.55M | -43.09M | -94.66M | -95.47M |
Financing Cash Flow | -56.81M | -58.55M | -41.86M | -27.92M | -22.20M | -10.73M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $1.15B | 84.23 | 2.19% | ― | -0.13% | -37.00% | |
75 Outperform | $719.33M | 23.26 | 8.87% | 2.90% | 9.44% | 53.83% | |
72 Outperform | $498.43M | 15.38 | 9.14% | ― | 5.83% | 33.50% | |
65 Neutral | £2.65B | 12.63 | 3.41% | 3.25% | 2.43% | -22.02% | |
62 Neutral | $718.68M | 37.86 | -1.73% | 3.29% | -7.98% | -124.63% | |
61 Neutral | $283.03M | 17.05 | 7.37% | ― | -16.95% | 66.04% | |
61 Neutral | $1.97B | ― | 8.26% | 1.54% | -34.58% | -240.25% |
On May 20, 2025, Robert Bodor stepped down as President and CEO of Proto Labs, Inc., and subsequently entered into a consulting agreement with the company to assist in management transition. The agreement, which includes a monthly fee and provisions for stock options, was extended on May 28, 2025, to continue through November 11, 2025, allowing Dr. Bodor to provide transitional consulting services.